Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
716 studies found for:    lenalidomide

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Condition: HIV-1 Infection
Interventions: Drug: Part A: lenalidomide dose escalation;   Drug: Part B: lenalidomide;   Drug: Part B: lenalidomide placebo
2 Active, not recruiting Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Conditions: Follicular Lymphoma;   Marginal Zone B-Cell Lymphoma;   MALT Lymphoma;   Lymphoma of Mucosa-Associated Lymphoid Tissue;   Lymphoma, Small Lymphocytic;   Waldenstrom Macroglobulinemia;   Mantle-Cell Lymphoma
Interventions: Drug: lenalidomide-low dose dexamethasone plus rituximab;   Drug: Lenalidomide + Rituximab
3 Active, not recruiting Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
4 Completed Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
5 Completed Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Condition: Advanced Cancers
Interventions: Drug: Lenalidomide;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Temsirolimus;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-fluorouracil
6 Completed
Has Results 		A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Condition: Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Interventions: Drug: Lenalidomide;   Drug: Recombinant human erythropoietin
7 Completed Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, endoxan, prednisone;   Drug: lenalidomide, endoxan, prednisone
8 Recruiting Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Vorinostat;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Drug: Enoxaparin;   Procedure: Stem Cell Transplant;   Drug: Palifermin
9 Completed
Has Results 		Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
Condition: Myelodysplastic Syndromes
Interventions: Drug: Lenalidomide 5 mg;   Drug: Lenalidomide 10 mg;   Drug: Placebo
10 Completed Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: lenalidomide
11 Active, not recruiting Ipilimumab and Lenalidomide in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Ipilimumab;   Drug: Lenalidomide
12 Terminated Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: All-Trans Retinoic Acid (ATRA)
13 Completed
Has Results 		Dasatinib in Combination With Revlimid (and Dexamethasone)
Condition: Multiple Myeloma
Interventions: Drug: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
14 Active, not recruiting A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: panobinostat;   Drug: lenalidomide
15 Active, not recruiting Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: lenalidomide, bortezomib and dexamethasone
16 Recruiting A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Rituximab;   Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Etoposide;   Drug: Prednisone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin
17 Recruiting Registry Study for Individuals With Del 5q Low or Intermediate-1 Risk MDS
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: Lenalidomide
18 Completed 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Condition: Leukemia
Interventions: Drug: 5-Azacytidine;   Drug: Lenalidomide
19 Active, not recruiting Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen;   Drug: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen;   Drug: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen;   Drug: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen;   Drug: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen;   Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen;   Drug: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance;   Drug: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance;   Drug: High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
20 Recruiting Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab (GA101)
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years